BiotechTube
arcoris bio

arcoris bio

Zurich, Switzerland· Est.
arcorisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Arcoris Bio is an early-stage biotech company commercializing a novel, enzyme-free DNA nanotechnology platform called MUSE® for multiplex biomarker detection. The platform addresses key limitations in sensitivity, specificity, and multiplexing capability for imaging techniques used in research and diagnostics, offering a simple, same-day workflow without specialized equipment. Founded by Simon Restrepo, Kaspar Binz, and Scott Fraser, the company targets the growing market for spatial biology and multiplexed assays in translational research, with a vision to eventually impact clinical diagnostics and personalized medicine.

OncologyImmunologyNeuroscienceGenetics

Technology Platform

MUSE® (Multiplex Universal Signal Enhancement) - an enzyme-free, self-assembling DNA nanotechnology for ultra-sensitive, specific, and multiplexed detection of proteins and nucleic acids across imaging and flow cytometry applications.

Opportunities

The rapid growth of spatial biology and demand for multiplexed tissue analysis in both research and clinical diagnostics presents a massive addressable market.
The platform's flexibility and simplicity allow for penetration into diverse applications (IHC, IF, FISH, FACS) and partnerships with large tool and diagnostic companies through white-label deals.

Risk Factors

Intense competition from well-funded public companies in spatial biology and established immunohistochemistry vendors.
Commercialization risk in convincing labs to adopt a new technology.
Long and costly regulatory pathway if pursuing clinical diagnostics.
Financial sustainability risk as a pre-profit private company.

Competitive Landscape

Arcoris Bio competes in the multiplex imaging space against companies like Akoya Biosciences (PhenoCycler, PhenoImager), NanoString (GeoMx, CosMx), and 10x Genomics (Xenium). Its key differentiation is an enzyme-free, equipment-agnostic chemistry that offers high sensitivity and true multi-omics (protein+RNA) multiplexing in a simple workflow, unlike some competitors that require specialized instruments or complex enzymatic steps.

More companies in Diagnostics & Precision Medicine →More companies in Switzerland →